FGF23 and secondary hyperparathyroidism: Wolf reported that etelcalcetide potently lowers FGF23 in patients with secondary hyperparathyroidism receiving hemodialysis and that the effect remains detectable among patients who receive concomitant treatments aimed at mitigating treatment-associated decreases in serum calcium [24].